People
-
Smartinhaler developer Nexus6 has raised NZ$1.6 million (US$1.34 million) from existing investors plus NZ$3 (US$2.5 million) from BioScience Managers, with additional funding expected to bring the total to NZ$5 million by the close of the… Read more . . .
-
Inhaled pharmaceutical company Prosonix has hired Cécile Miles as its Chief Business Officer. She had been Commercial Director, Europe for the Arrow Group, part of Watson (now Actavis) since May 2011. Prior to Arrow, she… Read more . . .
-
Pearl Therapeutics, which is developing several inhaled drugs, has announced that it has hired Michael Riebe as VP, Pharmaceutical Development and Research, effective immediately. Riebe, a past chair and current steering committee member of the… Read more . . .
-
Lars Borgström Consulting has joined the Medicon Valley Inhalation Consortium (MVIC), bringing the group of companies involved in inhalation product development in the Skåne-Copenhagen region to 14 members. Borgström, the first recipient of RDD’s Charles… Read more . . .
-
Discovery Laboratories has named John G. Cooper as President and CEO replacing W. Thomas Amick, who had been chairman of the board since March 2007 and CEO since October 2010. Cooper was Executive VP and… Read more . . .
-
Trimel Pharmaceuticals has named Tom Rossi as CEO to replace Bruce D. Brydon, who has stepped down as CEO. Rossi has been President of Trimel since he joined the company in August 2011 and also… Read more . . .
-
Alexza Pharmaceuticals has announced the appointment of J. Kevin Buchi to its board of directors. Buchi, who was Corporate Vice President, Global Branded Products at Teva Pharmaceutical Industries from October 2011 until May 2012, has… Read more . . .
-
Paul M. Young and Daniela Traini have moved from the Pharmacy Faculty at the University of Sydney to the Woolcock Institute of Medical Research (WIMR) in order to establish a new Respiratory Technology team at… Read more . . .
-
Prosonix has announced that Ken Cunningham will replace Jim Philips as Non-executive Chairman. Cunningham, who is also Chair of the company’s scientific advisory board, is a former CEO of Skyepharma. He has been a member… Read more . . .
-
Lightlake Therapeutics, which is developing intranasal naloxone to treat eating disorders, has announced the appointment of board member Kevin Pollack as Chief Financial Officer. Pollack joined the board of directors in April 2012. Lightlake Chief… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK